Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors

NCT02455596 is registered in ClinicalTrials.gov with The Affiliated Hospital of the Chinese Academy of Military Medical Sciences as lead sponsor.

NCT NCT02455596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02455596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
Lead sponsor
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2015
Completion date
December 31, 2016
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors